In conclusion, we have shown that monocytes and sCD163 in the circulation are potential prognostic biomarkers to predict disease progression in CRC patients, whereas the TAM densities and phenotypes in the primary tumor are not, thereby emphasizing the importance of the innate systemic immune system in CRC disease progression. The gene discussed is CD163; the disease is colorectal carcinoma.